Correlation Between EGFR Mutations and Serum Tumor Markers in Lung Adenocarcinoma Patients

Pan, Jinbing; Hou, Yuhong; Zhang, Guojun

doi:10.7314/apjcp.2013.14.2.695

Cited by 18 publications

(8 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conversely, the higher serum CEA level, the more EGFR gene mutation rate [15]. The same conclusion occured in recurrent lung adenocarcinoma patients after surgery [16].…”

Section: Discussionmentioning

confidence: 60%

Response to first-line erlotinib in a false EGFR mutation-negative patient with non-small-cell lung cancer: Make no assumptions

Deng¹,

Luo²,

Zhou³

2018

Open J Cell Protein Sci

View full text Add to dashboard Cite

His past medical history was notable for a 40 pack-year history of smoking. The carcinoembryonic antigen (CEA) serum level tested on January 31, 2013, was 276.37ug/l (the normal value of limitation is 5.0ug/l). Chest Computed tomography (CT) on February 5, 2013, showed a large number of miliary tubercles scattered in two lungs, which like metastatic lesions; one well-defi ned lesion lied in the posterior segment of the right upper lobe, whose edge is not smooth and diameter is about 2cm, among which pleural indentation sign and spicule sign should be found; a few of enlarged lymph nodes located in the mediastinum, among which the maximum diameter is 2.3cm. A CT-guided percutaneous needle biopsy was performed on February 18, 2013, and the pathological fi ndings showed adenocarcinoma. Imaging by PET-CT on February 28, 2013, showed intense fl uorodeoxyglucose activity in the right upper-lobe nodule, SUV max was7.3, diameter was about 2.92cmx2.72cm (Figure 1). Extensive fl uorodeoxyglucose activity was also evident within the following lymph nodes: double hilars, mediastinal, right neck, right subclavian, right upper trachea, retrocaval, and carinal. Of which the SUV max was 12.17 and the maximum diameter is 3.36cmx2.92cm .At the same time, it showed miliary nodules in double lung seem to be metastatic lesions with great possibility.

show abstract

“…Conversely, the higher serum CEA level, the more EGFR gene mutation rate [15]. The same conclusion occured in recurrent lung adenocarcinoma patients after surgery [16].…”

Section: Discussionmentioning

confidence: 60%

Response to first-line erlotinib in a false EGFR mutation-negative patient with non-small-cell lung cancer: Make no assumptions

Deng¹,

Luo²,

Zhou³

2018

Open J Cell Protein Sci

View full text Add to dashboard Cite

show abstract

“…In fact, some cell lines can be primarily resistant, retaining this feature from the primary tumor, or can acquire resistance with drug treatment. Several mechanisms involved in chemotherapy resistance have already been elucidated, including the high expression of drug efflux pumps, the increase in detoxification of chemotherapeutic drugs, the alteration of drug targets, and the inhibition of drug-induced apoptosis [81,82].…”

Section: D Models: Cell Lines and Primary Cell Culturesmentioning

confidence: 99%

Evolution of the Experimental Models of Cholangiocarcinoma

Massa

Varamo

Vita

et al. 2020

Cancers

View full text Add to dashboard Cite

Cholangiocarcinoma (CCA) is a rare, aggressive disease with poor overall survival. In advanced cases, surgery is often not possible or fails; in addition, there is a lack of effective and specific therapies. Multidisciplinary approaches and advanced technologies have improved the knowledge of CCA molecular pathogenesis, highlighting its extreme heterogeneity and high frequency of genetic and molecular aberrations. Effective preclinical models, therefore, should be based on a comparable level of complexity. In the past years, there has been a consistent increase in the number of available CCA models. The exploitation of even more complex CCA models is rising. Examples are the use of CRISPR/Cas9 or stabilized organoids for in vitro studies, as well as patient-derived xenografts or transgenic mouse models for in vivo applications. Here, we examine the available preclinical CCA models exploited to investigate: (i) carcinogenesis processes from initiation to progression; and (ii) tools for personalized therapy and innovative therapeutic approaches, including chemotherapy and immune/targeted therapies. For each model, we describe the potential applications, highlighting both its advantages and limits.

show abstract

“…Some data indicate that the diagnosis of adenocarcinoma or squamous cell carcinoma can be established in 50-70% of cases only by morphological examination of small biopsy preparations or cytology. IHC staining can help determine the histological type up to the subtypes so that the final diagnosis is not only Non-Small-Cell Lung Cancer but also up to the subtype (4).…”

Section: Introductionmentioning

confidence: 99%

Relationship of TTF-1 and EGFR on Lung Adenocarcinoma at Dr. Saiful Anwar General Hospital Malang

gaol

Pratiwi

Putra

et al. 2020

JKB

View full text Add to dashboard Cite

<p>There is a correlation between mutation of Epidermal Growth Factor Receptor (EGFR) and lung adenocarcinoma. Unfortunately, examination for EGFR mutation is difficult because surgery must be conducted to obtain the best specimen. Thyroid Transcription Factor-1 (TTF-1) is a marker for lung adenocarcinoma. This observational study took place at Dr. Saiful Anwar Hospital from stored biological materials from 2013-2018. Samples were lung adenocarcinoma patients that undergo EGFR examination. Data then analyzed using Fischer's Exact Test to determine the relationship between EGFR and TTF-1. Specificity/sensitivity value is 0.75/0.90, p: 0.617, odds ratio 0.333 (0.032-3.515). However, Receiver Operating Characteristic (ROC) curve of TTF- 1 show AUC 0.614 (95CI, 0.35- 0.878). TTF-1 examination has a moderate strength in determining EGFR mutation on lung adenocarcinoma patients at Dr. Saiful Anwar Hospital. </p>

show abstract

Correlation Between EGFR Mutations and Serum Tumor Markers in Lung Adenocarcinoma Patients

Cited by 18 publications

References 34 publications

Response to first-line erlotinib in a false EGFR mutation-negative patient with non-small-cell lung cancer: Make no assumptions

Response to first-line erlotinib in a false EGFR mutation-negative patient with non-small-cell lung cancer: Make no assumptions

Evolution of the Experimental Models of Cholangiocarcinoma

Relationship of TTF-1 and EGFR on Lung Adenocarcinoma at Dr. Saiful Anwar General Hospital Malang

Contact Info

Product

Resources

About